Relationships of lipocalin 2 with breast tumorigenesis and metastasis

Breast cancer is one of the most common cancers in women worldwide and accounts for one‐sixth of cancer deaths in the United States. Breast cancer consists of a heterogeneous group of tumours classified into five types, in which the HER2/neu positive and the basal type (most are ER and HER2 negative...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cellular physiology 2011-02, Vol.226 (2), p.309-314
Main Authors: Leng, Xiaohong, Wu, Yun, Arlinghaus, Ralph B.
Format: Article
Language:English
Subjects:
Acute-Phase Proteins - genetics
Acute-Phase Proteins - metabolism
Animals
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Breast Neoplasms - genetics
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Epithelial-Mesenchymal Transition
Female
Humans
Iron - metabolism
Leukemia - metabolism
Leukemia - pathology
Lipocalin-2
Lipocalins - genetics
Lipocalins - metabolism
Matrix Metalloproteinase 9 - metabolism
Neoplasm Metastasis
Proto-Oncogene Proteins - genetics
Proto-Oncogene Proteins - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Breast cancer is one of the most common cancers in women worldwide and accounts for one‐sixth of cancer deaths in the United States. Breast cancer consists of a heterogeneous group of tumours classified into five types, in which the HER2/neu positive and the basal type (most are ER and HER2 negative) have the worst clinical prognosis. In recent years, prognostic/predictive markers such as ER/PR or HER2/neu have been widely used in the selection of the optimal breast cancer treatments for individual patients, which have been proven to be very effective in disease control. These results suggest that further examination of the molecular mechanisms underlying the breast tumorigenesis and identification of the potential biomarkers in different types of breast cancers will greatly benefit clinical diagnosis and facilitate the design of more effective personalized therapies to increase patient survival. This review aims to summarize recent research findings on lipocalin 2 (LCN2), a newly identified biomarker and a potential therapeutic target for breast cancer, and the possible mechanisms underlying its role in tumorigenesis and metastasis. J. Cell. Physiol. 226: 309–314, 2011. © 2010 Wiley‐Liss, Inc.
ISSN:0021-9541
1097-4652
DOI:10.1002/jcp.22403